journal article·2021-03-10

Optimized Combination of Photodynamic Therapy and Chemotherapy Using Gelatin Nanoparticles Containing Tirapazamine and Pheophorbide a

Donghyun Lee, Seok-young Jang, Soonmin Kwon, Yeeun Lee, Eunyoung Park, Heebeom Koo

Publisher page

Abstract

In combination therapy, synergetic effects of drugs and their efficient delivery are essential. Herein, we screened 12 anticancer drugs for combination with photodynamic therapy (PDT) using pheophorbide a (Pba). On the basis of combination index (CI) values in cell viability tests, we selected tirapazamine (TPZ) and developed self-assembled gelatin nanoparticles (NPs) containing both Pba and TPZ. The resulting TPZ-Pba-NPs showed a synergetic effect to kill tumor cells because TPZ was activated under the hypoxic conditions that originated from the PDT with Pba and laser irradiation. After they were injected into tumor-bearing mice via the tail vein, TPZ-Pba-NPs showed 3.17-fold higher blood concentration and 4.12-fold higher accumulation in tumor tissue 3 and 24 h postinjection, respectively. Upon laser irradiation to tumor tissue, TPZ-Pba-NPs successfully suppressed tumor growth by efficient drug delivery and synergetic effects in vivo. These overall results suggest that in vitro screening of drugs based on CI values, mechanism studies in hypoxia, and real-time in vivo imaging are promising strategies in developing NPs for optimized combination therapy.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Photodynamic Therapy Research Studies · Cancer, Hypoxia, and Metabolism

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Medical Life Sciences, Department of Biomedicine & Health Sciences, and Catholic Photomedicine Research Institute, College of Medicine, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul, 06591, Republic of Korea

Funding

National Research Foundation of Korea

References (37)

Show source-provided references
1. 10.1021/cr900300p10.1021/cr900300p ↗
2. 10.1021/cr900236h10.1021/cr900236h ↗
3. 10.1038/s12276-020-0384-210.1038/s12276-020-0384-2 ↗
4. 10.1039/C6CS00271D10.1039/C6CS00271D ↗
5. 10.1007/s40005-017-0377-x10.1007/s40005-017-0377-x ↗
6. 10.7150/ijbs.1285210.7150/ijbs.12852 ↗
7. 10.1039/C9TB02752A10.1039/C9TB02752A ↗
8. 10.1158/0008-5472.CAN-11-374410.1158/0008-5472.CAN-11-3744 ↗
9. 10.1021/acsami.7b0092710.1021/acsami.7b00927 ↗
10. 10.1021/acsami.9b1907310.1021/acsami.9b19073 ↗
11. 10.18632/oncotarget.1672310.18632/oncotarget.16723 ↗
12. Kang X. · Cancer Biol. Med. · 2015 · 12 · 362
13. 10.1016/j.biomaterials.2016.04.02710.1016/j.biomaterials.2016.04.027 ↗
14. 10.1038/nrd452410.1038/nrd4524 ↗
15. 10.1158/0008-5472.CAN-09-194710.1158/0008-5472.CAN-09-1947 ↗
16. 10.1124/pr.58.3.1010.1124/pr.58.3.10 ↗
17. 10.1039/C2CS15261D10.1039/C2CS15261D ↗
18. 10.1021/ar200013810.1021/ar2000138 ↗
19. 10.1038/nrc.2016.10810.1038/nrc.2016.108 ↗
20. 10.1126/science.812824510.1126/science.8128245 ↗
21. 10.1016/0026-2862(86)90018-X10.1016/0026-2862(86)90018-X ↗
22. Matsumura Y. · Cancer Res. · 1986 · 46 · 6387
23. 10.1016/j.addr.2017.06.00310.1016/j.addr.2017.06.003 ↗
24. 10.1016/j.addr.2015.10.01910.1016/j.addr.2015.10.019 ↗
25. 10.1016/j.addr.2017.03.00110.1016/j.addr.2017.03.001 ↗
26. 10.1016/j.jphotobiol.2009.04.01210.1016/j.jphotobiol.2009.04.012 ↗
27. 10.1016/j.addr.2003.08.01610.1016/j.addr.2003.08.016 ↗
28. 10.1007/s40820-019-0298-510.1007/s40820-019-0298-5 ↗
29. 10.1080/1060132090271937010.1080/10601320902719370 ↗
30. 10.1039/C8CS00304A10.1039/C8CS00304A ↗
31. 10.1016/j.biomaterials.2019.11950010.1016/j.biomaterials.2019.119500 ↗
32. 10.1016/j.dyepig.2020.10820710.1016/j.dyepig.2020.108207 ↗
33. 10.1517/1354378080256725010.1517/13543780802567250 ↗
34. 10.1016/j.ejps.2017.06.03010.1016/j.ejps.2017.06.030 ↗
35. 10.1021/am501932s10.1021/am501932s ↗
36. 10.1080/17425247.2016.121846410.1080/17425247.2016.1218464 ↗
37. 10.1016/j.addr.2008.08.00510.1016/j.addr.2008.08.005 ↗